Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 3Completed 3Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1Dermatologic 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 70Cyclophosphamide 44Bortezomib 41Lenalidomide 25Melphalan 24Thalidomide 19pomalidomide 17daratumumab 14fludarabine 13carfilzomib 10Filgrastim 8Doxorubicin 8Busulfan 6isatuximab 5Prednisone 5Peripheral Blood Stem Cell Transplantation 5Calcium Dobesilate 5Bendamustine Hydrochloride 5selinexor 4sargramostim 4fludarabine phosphate 4Surveys and Questionnaires 4Etoposide 4Clarithromycin 4liposomal doxorubicin 3ixazomib 3dexamethasone acetate 3Radiotherapy 3Neoadjuvant Therapy 3Mycophenolic Acid 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × romidepsin × Plasma cell × Clear all
NCT00431990 2011-08-12

A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Unknown
40 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡